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Abstract
Five new phenolic siderophores 1–5 were isolated from the organic extract of a culture broth in a modified SGG medium of Pseu-
domonas sp. UIAU-6B, obtained from sediments collected from the Oyun river in North Central Nigeria. The structure of the new
compounds, pseudomonin A–C (1–3) and pseudomobactin A and B (4 and 5) isolated alongside two known compounds,
pseudomonine (6) and salicylic acid (7), were elucidated based on high-resolution mass spectrometry, 1D and 2D NMR analyses.
The absolute configuration of the threonine residue in compounds 1–5 was determined by Marfey analysis. The antimicrobial eval-
uation of compound 4 exhibited the most potent activity against vancomycin-sensitive Enterococcus faecium VS144754, followed
by 3 and 5, with MIC values ranging from 8 to 32 µg/mL. Compounds 2 and 3 exhibited moderate activity against Mycobacterium
tuberculosis H37Rv, with MIC values of 7.8 and 15.6 µg/mL, respectively. Plausible biosynthetic hypotheses toward the new com-
pounds 1–5 were proposed.
Introduction
The introduction of antimicrobial drugs in the mid-20th century
has had an unprecedented positive impact on human health, but
the current threat of multiple drug resistance may well roll back
all these past achievements [1]. One way out of this is an exten-
sive search for novel bioactive natural products from microbial
sources [2,3].
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Figure 1: Structures of the new phenolic siderophores 1–5, pseudomonine (6), and salicylic acid (7).
There is focus on the genus Pseudomonas for scientific research
due to its widespread distribution in water, soil, and extreme
habitats, including the exceptional ability to colonize the rhizos-
phere of host plants, serving as a microbial biocontrol [4,5].
This genus, belonging to the Gram-negative proteobacteria is
diverse in nature and possesses unique environmental adapt-
ability which shows in their versatile metabolism [6-8]. They
are prolific producers of natural products with broad-spectrum
biological functions which include antifungal [9-11] and anti-
bacterial activities [12-14]. Natural product scaffolds isolated
from species of this genus have contributed immensely as leads
to drug discovery and development [15]. For instance, clofaz-
imine [16], the antimycobacterial agent used for the treatment
of leprosy and inflammation was inspired by the natural
product phenazine [17,18]. Also, pseudomononic acid
(mupirocin) isolated from Pseudomonas fluorescens by Fuller
and co-workers in 1971 was discovered to possess novel anti-
bacterial activities against 310 clinical isolates of Staphylo-
coccus aureus with MIC values ranging from 0.06 to
0.25 µg/mL. Mupirocin was later developed for topical usage
[19-22].
Several siderophores of hydroxamate, catecholate or phenolic
scaffolds such as cepabactin [23], pyochelin [24,25],
pyoverdines [26], vulnibactin [27], and pseudomonine [28] are
produced under iron deficiency by various Pseudomonas
species to acquire iron which is essential for cell metabolism
and growth [29,30]. Studies show that siderophore–antibiotic
complexes may be used as a Trojan horse strategy in which the
antibiotics utilize the iron-siderophore transporting system as a
cellular entry gateway [31,32]. Thus far, a few Pseudomonas-
derived siderophores including ferrocins [33], thio-
quinolobactin [34], and (+)-(S)-dihydroaeruginioc acid [35]
have been reported as active antimicrobial agents.
Our continued exploration of new bioactive compounds from
microbial sources led to the isolation of Pseudomonas sp.
UIAU-6B from sediments collected from the Oyun river in
North Central Nigeria. Herein, we report the isolation and struc-
ture elucidation of seven secondary metabolites including five
new (1–5), and two known phenolic siderophores (6 and 7)
[28,36,37], together with their antimicrobial activities against
vancomycin-sensitive Enterococcus faecium VS144754 and
Mycobacterium tuberculosis strain H37Rv. A plausible biosyn-
thetic hypothesis is proposed towards the new compounds 1–5.
Results and Discussion
The preliminary LC–MS analysis of the methanolic extract
from a small-scale culture of Pseudomonas sp. UIAU-6B in
modified SGG medium indicated the presence of some interest-
ing peaks with molecular ions which gave no hits when they
were searched in natural product databases (Antibase). At the
same time, the 1H NMR fingerprints suggested the presence of
interesting aromatic compounds and led to a decision to under-
take large-scale fermentation. The total crude extract (8.2 g)
was subsequently subjected to a combination of fractionations
(Kupchan partition and MPLC), and purification by reversed-
phase semipreparative HPLC to obtain five new secondary
metabolites 1–5 including pseudomonin A–C (1–3) and pseudo-
mobactins A and B (4 and 5). The two known compounds,
pseudomonine (6) and salicylic acid (7) were also isolated as
the major constituents of the extracts and their structures were
determined by analysis of HRESIMS, 1D and 2D NMR data
(see Figure 1 and Supporting Information File 1 for details)
which were comparable with those reported in the literature
[28,36,37].
Pseudomonin A (1) was isolated as a yellowish compound. The
molecular formula of C11H15O4N2 with 6 degrees of unsatura-
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Table 1: 1H and 13C NMR data of pseudomonin A–C (1–3).a
compound 1 compound 2 compound 3
position δC, type δH (J in Hz) δC, type δH ( J in Hz) δC, type δH (J in Hz)
1 162.9, C 162.8, C 162.8, C
2 118.2, CH 6.96, dd (8.7, 1.8) 118.4, CH 6.96, d (8.7) 118.4, CH 6.98, m
3 137.2, CH 7.52, td (8.7, 1.8) 137.5, CH 7.52, td (8.7, 1.7) 137.4, CH 7.54, td (8.7, 1.8)
4 120.2, CH 6.94, td (8.7, 1.8) 120.6, CH 6.94, dd (8.7, 1.7) 120.5, CH 6.95, m
5 131.6, CH 7.99, dd (8.7, 1.8) 131.7, CH 7.95, dd (8.7, 1.7) 131.7, CH 7.98, dd (8.7, 1.8)
6 113.2, C 113.1, C 113.2, C
7 170.0, C 169.9, C 170.0, C
9 57.6, CH 4.20, d (6.5) 57.7, CH 4.21, d (6.5) 57.8, CH 4.13, d (6.5)
10 169.4, C 167.7, C 167.2, C
11 71.1, CH 5.67, qd (6.6, 6.5) 71.0, CH 5.61, qd (6.6, 6.5) 71.3, CH 5.53, dq (6.5, 6.5)
12 16.7, CH3 1.54, d (6.6) 17.0, CH3 1.49, d (6.6) 16.9, CH3 1.43, d (6.5)
15 39.3, CH2 3.62, dt (13.8, 6.8);
3.52, dt (13.8, 6.8)
42.1, CH2 3.44, dt (13.7, 7.2)
3.64, dt (13.7, 7.2)
16 25.3, CH2 2.92, m 36.1, CH2 2.79, m
17 132.5, C 140.0, C
18 117.5 CH 7.33, d (0.6)
20 135.0, CH 8.73, d (0.6)
18’/22 129.5, CH 7.16, m
19’/21 129.6, CH 7.22, m
20’ 127.5, CH 7.14, m
aSpectra acquired at 600 MHz in CD3OD for 1H NMR and at 150 MHz in CD3OD for 13C NMR.
tion was established by high-resolution ESI-Orbitrap-MS that
revealed a molecular ion at m/z 237.0874 (calcd for
C11H13N2O4−, 237.0880). A thorough analysis of 1H and 2D
NMR data (see Table 1 and Supporting Information File 1)
showed four aromatic methines, two aliphatic methines, one
methyl, and four quaternary carbons signals at δC 162.9 (C-1),
113.2 (C-6), δC 170.0.0 (C-7), and δC 169.4 (C-10).
The downfield methine proton signals at δH 6.96 (d, J = 8.7,
1.8 Hz, H-2), 7.52 (td, J = 8.7, 7.2, 1.8 Hz, H-3), 6.94 (td, J =
8.7, 1.8 Hz, H-4), and δH 7.99 (dd, J = 8.1, 1.8 Hz, H-5) were
consistent with a 1,2-disubstituted aromatic benzene ring of a
salicylic acid unit, confirmed by long-range correlations ob-
served in the HMBC spectrum from H-2, H-4 to C-6 (δC 113.2),
and H-5 to the quaternary carbon C-7 (δC 170.0). On the other
hand, the COSY spectrum confirmed the presence of a
CH3–CH–CH spin system (H3-12, H-11, and H-9) reminiscent
of a threonine unit. Remarkably, this unit was found to be at-
tached in “reverse” fashion compared to the isoxazolidinone
unit in compound 6. The connection via an ester bond of the
oxygenated sp3 methine C-11 (δC 71.1) with the carbonyl group
of salicylic acid (C-7) was supported by a HMBC cross-peak
from H-11 (δH 5.61) to C-7 (δC 170.0), and thus confirmed the
structure of pseudomonin A (1).
Pseudomonin B (2) was isolated as a yellowish solid whose
HRESI mass spectrum gave a molecular ion at m/z 333.1561
[M + H]+ that corresponded to a molecular formula of
C16H20N4O4 (calcd for C16H21N4O4+, 333.1557) with
9 degrees of unsaturation. The detailed analysis of 1H and 2D
NMR spectra (see Table 1 and Supporting Information File 1)
suggested the presence of both, the salicylic acid (H-2/H-3/H-4/
H-5) and the linear threonine subunits found in 1, which were
supported by the HMBC correlations shown in Figure 2. The
major difference in comparison with compound 1 was the pres-
ence of a histamine subunit (H-15 to H-20), whose identity was
established by COSY correlations observed between H-15 and
H-16 and the key HMBC correlations depicted in Figure 2.
Pseudomonin C (3) was isolated as white amorphous solid.
Its molecular formula of C19H22N2O4 was deduced from the
analysis of its HRESI mass spectrum (m/z 343.1653 [M + H]+,
calcd for C19H23N2O4+, 343.1652) accounting for ten degrees
of unsaturation. A prominent peak at m/z  325.1551
[(M + H − OH]+ (calcd for C19H21N2O3+, 325.1547) due to a
facile loss of H2O from the molecular ion was observed. A thor-
ough inspection of 1D and 2D spectra (see Table 1 and Support-
ing Information File 1) confirmed the resonance signals charac-
teristic of both, the salicylic acid (H-2 to H-5) and the linear
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Figure 2: Key HMBC and 1H-1H COSY correlations.
Table 2: 1H and 13C NMR data of pseudomobactin A (4) and B (5).a
compound 4 compound 5
position δC, type δH, (J in Hz) δC, type δH, (J in Hz)
1 161.1, C 161.1, C
2 117.7, CH 6.96, d (8.3) 117.7, CH 6.99, d (8.3)
3 135.0, CH 7.41, td (8.3, 1.7) 135.1, CH 7.43, td (8.3, 1.6)
4 119.9, CH 6.90, td (7.4, 1.7) 120.0, CH 6.92, t (7.4, 1.7)
5 129.5, CH 7.68, dd(7.4, 1.7) 129.5, CH 7.67, dd (7.4, 1.7)
6 111.6, C 111.6, C
7 167.8, C 168.0, C
9 75.5, CH 4.46, d (7.3) 75.8, CH 4.38, d (7.3)
10 175.6, C 172.9, C
11 80.6, CH 4.90, qd (6.3, 7.3) 80.6, CH 4.78, dq (6.3, 7.3)
12 21.4, CH3 1.57, d (6.3) 21.3, CH3 1.51, d (6.3)
14 41.9, CH2 3.44, dt (13.6, 7.2), 3.51, dt (13.6, 7.2)
15 36.3, CH2 2.82, t (7.2)
16 140.2, C
17/21 129.9, CH 7.20, m
18/20 129.5, CH 7.22, m
19 127.3, CH 7.15, m
aSpectra acquired at 600 MHz in CD3OD for 1H NMR and at 150 MHz in CD3OD for 13C NMR.
threonine (H-9 to H3-12) conjugate present in compounds 1 and
2, and also displayed a new set of signals compatible with the
replacement of the histamine unit in 2 with a phenylethylamine
moiety (H-15 to H-22). This was supported by the COSY and
HMBC correlations shown in Figure 2, and thus confirmed the
structure of pseudomonin C (3).
Pseudomobactin A (4) was obtained as a reddish solid. The
HRESI mass spectrum revealed a molecular ion at m/z 221.0923
([M + H]+, calcd for C11H13N2O3+, 221.0921) corresponding to
a molecular formula of C11H12N2O3 with seven degrees of
unsaturation. The integration of the 1H NMR spectrum (see
Table 2 and Supporting Information File 1) identified two spin
systems consistent with the presence of the 1,2-disubstituted ar-
omatic ring of salicylic acid in compounds 1–3 and a threonine
unit (H-9 to H-12) that differed from compounds 1–3 due to the
observed deshielded chemical shifts of the methine carbons C-9
(δC 75.5) and C-12 (δC 21.4), suggestive of the presence of an
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Figure 3: Plausible biosynthetic hypotheses of compounds 1–5.
oxazoline ring similar to that found in vulnibactin [27]. The key
HMBC cross-peaks (Figure 2 and Supporting Information
File 1) from H-9 (δH 4.46, J = 7.3 Hz, d) and H-11(δH 4.90, qd,
J = 6.3, 7.3 Hz) to carboxamide C-10 (δC 175.6) and C-7
(δC 167.8), confirmed the proposed structure which we named
pseudomobactin A.
Compound 5 was obtained as a reddish solid. The HRESIMS
gave a prominent molecular ion at m/z 325.1550 ([M + H]+ cor-
responding to a molecular formula of C19H20N2O3 with eleven
degrees of unsaturation. The information afforded by inte-
grating the signals of the 1H NMR and the full 2D spectra
(Table 2 and Supporting Information File 1) of compound 5
showed resonance signals consistent with compound 4
connected to the same 2-phenylethylamine moiety present in 3
(H-14 to H-21). This was supported by HMBC cross-peaks
(Figure 2) between the diastereotopic protons H2-14 and
carboxamide C-10 (δC 172.9) and the quaternary carbon C-16
(δC 140.2), between H2-15 and H-18/20 to the quaternary car-
bon C-16, and a strong correlation from H-15 and H-19 to
C-17/20 (δC 129.9). The new oxazoline derivative 5 was named
pseudomonbactin B.
The absolute configuration of the threonine residue in com-
pounds 1–5 was assigned as ʟ, based on the derivatization with
Marfey’s reagent of compound 2 and 4 hydrolysates, which
represented the two distinctive structural scaffolds and chemi-
cal shifts followed by HPLC analysis of the derivatized amino
acid residuals in the hydrolysate and threonine standards (see
Supporting Information File 1).
The biosynthesis hypotheses of compounds 1–5 were proposed
to have originated as an extension of the reported pseudomo-
nine (6) biosynthesis [37-40] via the salimethyloxazolinyl-
thioester intermediate 8 (Figure 3). We speculated that com-
pounds 1–3 occur through deviation of the salimethyloxa-
zolinyl-thioester intermediate 8 from the assembly line via an
unusually facile C–N-bond opening of the ring to generate an
ester bond, and followed directly by amination (+ NH3), the ad-
dition of histamine and phenethylamine units to form com-
pounds 1, 2, and 3, respectively (Figure 3). Biochemical studies
show that histamine and phenethylamine moieties were pro-
duced from histidine and phenylalanine substrates by a decar-
boxylase enzyme [41-43]. Pseudomobactin A (4) was proposed
logically to have formed through direct amination of the
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unstable salimethyloxazolinyl-thioester intermediate followed
by dehydration [44]. The incorporation of the decarboxylated
phenylalanine by a nucleophilic unit to the intermediate
salimethyloxazolinyl-thioester resulted in the formation of com-
pound 5 without a rearrangement to isooxazolidinone owing to
lack of N–OH in the phenylalanine unit [40].
Biological evaluation
Compounds 1–7 were evaluated for their antimicrobial activi-
ties against methicillin-resistant Staphylococcus aureus
(MRSA), methicillin-sensitive Staphylococcus aureus (MSSA),
Escherichia coli, Acinetobacter Bahmani, vancomycin-resis-
tant E. faecium VanA15167, vancomycin-sensitive E. faecium
VS144756, and M. tuberculosis H37Rv (see Table S8 in Sup-
porting Information File 1). Compound 4 was the most potent
against Vancomycin-sensitive E. faecium VS144754, with a
MIC value in a range of 8–16 µg/mL, followed by compounds 3
and 5, which showed MIC values of 16 and 32 µg/mL, respec-
tively. Additionally, compounds 2 and 3 exhibited moderate
antitubercular activity with MICs of 7.8 and 15.6 µg/mL, re-
spectively. Besides, compound 5 showed low activity (MIC of
125 µg/mL) against the latter pathogen. None of the com-
pounds inhibited the growth of E. coli, A. baumannii, MRSA,
MSSA, or E. faecium VanA15167 at the highest concentration
(64 µg/mL) tested (see Supporting Information File 1).
Conclusion
In summary, we have isolated seven natural products, including
five new phenolic siderophores (1–5) that have not been re-
ported in the literature and their biosynthetic pathways were
proposed as a rational extension of the previously reported
metabolite, pseudomonine (6), one of the major constituents of
the extract from the culture broth of Pseudomonas sp. UIAU-
6B. The new compounds 1–5 are interesting chemical entities
consisting of scaffolds with different functionalities that could
be exploited for further biological investigation and
structure–activity relationship (SAR) studies. To the best of our
knowledge, the breakage of the C–N bond of the salimethyloxa-
zolinyl-thioester intermediate leading to an ester bond that
resulted in the formation of compounds 1–3 constitutes new




IR spectra were acquired on a Perkin Elmer Spectrum Two
FT-IR spectrometer equipped with an ATR diamond cell.
Optical rotations were measured on an ADP 410 digital
Polarimeter (Bellingham + Stanley Ltd, United Kingdom).
NMR spectra were recorded on Bruker AVANCE III spectrom-
eters at 500/600 MHz for 1H NMR and 125/150 MHz for
13C NMR operating with a helium-cooled cryoprobe and a
liquid nitrogen ‘Prodigy’ cryoprobe, respectively. 1H and 13C
chemical shifts were referenced to the residual non-deuterated
solvent peak (3.31 and 49.1 ppm for CD3OD). The multiplici-
ties of 13C NMR were determined by an edited heteronuclear
single quantum coherence (HSQC) experiment. HRESIMS
spectra were obtained using a Thermo Instruments MS system
(LTQ XL/LTQ Orbitrap Discovery) coupled to a thermo instru-
ments HPLC system (Accela PDA detector, Accela PDA
autosampler, and Accela pump) or an Agilent 6540 in ESI-TOF
MS coupled to an HPLC Agilent 1290 Infinity equipped with a
diode array detector (DAD). Chromatographic fractionation was
carried out on a Reveleris preparative flash system equipped
with a reversed-phase Phenomenex strata® C18-E cartridge
(55 µm, 70 Å, 2 g/12 mL). HPLC purification was done with an
Agilent HPLC apparatus (1200 series) equipped with a binary
pump, diode array detector (G1315B), sunfire reversed-phase
column C18 (5 µm, 10 × 250 mm), Phenomenex C18 (5 µm,
9.4 × 250 mm), or ACE C18 (5 µm, 9.4 × 250 mm) columns,
and a mobile phase solvent gradient consisting of H2O (Milli-Q
filter water 18 MΩ·cm, Millipore, Germany), 100% MeOH
(Sigma-Aldrich, UK), and TFA (Sigma-Aldrich, UK).
Bacterial isolation and identification
The bacterial strain was isolated from soil sediments collected
from the Oyun river in North Central Nigeria (8.4799° N,
4.5418° W). The sediment samples were air-dried at room
temperature for 48 h. Ten grams (dry weight equivalent)
were suspended in 100 mL of sterile distilled water, vortexed
at high speed, and 1 mL of diluent was serially diluted
(10−2 and 10−4). Isolation of the bacterium (UIAU-6B) using a
spread plate technique was performed by inoculating an 0.1 mL
aliquot on pseudomonas agar base augmented with
cephalosporin–fucidin–cetrimide-selective supplement (Pseudo-
monas–CFC agar SR0103, Oxoid Ltd., Reading, UK) and incu-
bated at 28 °C for five days. The pure colony of the UIAU-6B
strain was purified by repeated subculture on pseudomonas agar
base plates. The strain was identified by analysis of the molecu-
lar DNA sequencing of its 16S rDNA and the sequence ob-
tained was compared with the Genbank database using the
BLAST search of the National Center for Biotechnology Infor-
mation (NCBI) which confirmed it to be homologous by
99.06% in the phylogenetic tree as Pseudomonas sp. (see Figure
S49A, in Supporting Information File 1).
Fermentation
The small-scale culture was prepared by inoculating a stock cul-
ture of Pseudomonas UIAU-6B (2 mL) in a 1000 mL baffled
Erlenmeyer flask containing 150 mL modified SGG medium
(glycerol 10 g, corn steep powder 2.5 g, peptone 5 g, soluble
starch 10 g, yeast extract 2 g, CaCO3 3 g, NaCl 1 g, in 1 L H2O,
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pH adjusted to 7.3) [45]. The flask was left shaking at 160 rpm
in a closed system shaker for ten days at 28 °C. Subsequently,
7.5 g of HP-20 resin were added to the fermentation cultures
under sterile conditions and incubated for the next 7 h at the
same shaking conditions. The broth cultures were filtered under
vacuum and the HP-20 resin was extracted with methanol
(200 mL) to obtain 1.2 g of crude extract from which a
0.5 mg/mL solution was prepared for preliminary LC–MS
chemical profiling.
Large-scale cultures (6000 mL) were prepared by inoculating
twenty 2000 mL baffled Erlenmeyer flasks containing 300 mL
modified SGG medium with the seed culture of Pseudomonas
UIAU-6B (50 mL). The seed culture (50 mL) was prepared by
inoculating a 250 mL baffled Erlenmeyer flask containing a
modified SGG medium with a stock culture of Pseudomonas
UIAU-6B (2 mL) and growth for 3 days. The entire fermenta-
tion process employed similar conditions as the small-scale cul-
ture.
Extraction and isolation
After the incubation, 15 g of HP-20 resin were added to each
flask under sterile conditions and allowed to shake for 7 hours
before the HP20 resin was filtered and subsequently extracted
with methanol (3 × 500 mL) followed by ethyl acetate
(3 × 300 mL). The combined organic extract was dried under
reduced pressure, to yield 8.2 g of crude extract. The extract
(8.2 g) was dissolved in H2O and CH2Cl2 (700 mL, 50% v/v)
and placed in a separating funnel for 5 min to allow for proper
separation of the constituent mixture between the aqueous
(6.21 g) and organic phases (1.99 g) [46]. The dichloromethane
fraction (1.99 g) was chromatographed on a reversed-phase
preparative flash system consisting of a C-18 (KP-C18-HS™,
40 × 150 mm) stationary phase cartridge equipped with
variable UV and ELSD detectors to monitor the run at
210, 230, and 254 nm) with the combination of isocratic
and linear gradient solvent system (80–20% H2O/MeOH
for 20 min followed by a linear gradient from 20%
to 50% MeOH over 10 min, 50% MeOH for 5 min, 50% to 70%
MeOH/H2O for 15 min, 70% MeOH for 5 min, 70% to 100%
MeOH/H2O for 15 min and 100% MeOH over 20 min) at a
flow rate of 10 mL/min. Four fractions were obtained: FD1
(0.8 g, tR 8.2–12.0 min), FD2 (0.35 g, tR 27–40 min), FD3
(0.24 g, tR 41–57 min), and FD4 (0.45 g, tR 58–70 min).
Fraction FD1 (0.8 g) was subjected to reversed-phase semi-
preparative HPLC on a Sunfire column C18 (5 µm,
10 × 250 mm) with a linear gradient of H2O/MeOH 80–20%
over 30 min at a flow rate of 2 mL/min, yielding compounds 7
(70 mg, tR 10 min), 6 (300 mg, tR 15.1 min), and 1 (2.2 mg,
tR 23.4 min).
Fraction FD2 (0.35 g) was purified with the same HPLC sol-
vent system and stationary phase as FD1 to obtain compound 4
(3.9 mg, tR 22.2 min).
Fraction FD3 (0.35 g) was subjected to HPLC on a reversed-
phase Phenomenex column C18 (5 µm, 10 × 250 mm) with a
mobile phase gradient system of H2O/MeOH 80–20% and
0.01% TFA for 35 min at a flow rate of 2 mL/min to afford
compound 2 (15.3 mg, tR 19.1 min).
The final dichloromethane subfraction FD4 (0.45 g) was rechro-
matographed by reversed-phase HPLC using a Sunfire column
C18 (5 µm, 10 × 250 mm) and a variable solvent system
starting with H2O/MeOH 70:30 isocratic elution over 5 min,
followed by a linear gradient to 100% MeOH over 20 min at a
flow rate of 1.8 mL/min to yield compounds 3 (1.2 mg,
tR 16.8 min) and 5 (1.8 mg, tR 18.9 min).
Pseudomonin A (1): yellowish oil; [α]D25 −9.5 (c 0.02, MeOH);
UV (MeOH) λmax, nm (log ε): 276 (3.23); IR (cm−1) νmax:
3333, 1677 1660, 1538, 1493, 1203, 1138; NMR data, see
Table 1; HRESIMS (m/z): [M − 1]− calcd for C11H13N2O4,
237.0880; found, 237.0874, Δ = −2.53 ppm.
Pseudomonin B (2): yellowish oil; [α]D25 −13.3 (c 0.05,
MeOH); UV (MeOH) λmax, nm (log ε): 297 (3.64); IR (cm−1)
νmax: 3137, 1673, 1660; NMR data, see Table 1; HRESIMS
(m/z): [M + H]+ calcd for C16H21O4N4, 333.1557; found
333.1561, Δ = 1.20 ppm.
Pseudomonin C (3): white amorphous solid; [α]D25 −45.6
(c 0.02, MeOH); UV (MeOH) λmax, nm (log ε): 299 (3.85); IR
(cm−1) νmax: 3341, 2927, 1670, 1633, 1205; NMR data, see
Table 1; HRESIMS (m/z): [M + H]+ calcd for C19H23N2O4,
343.1652; found, 343.1653, Δ = 2.01 ppm.
Pseudomobactin A (4): yellow amorphous solid; [α]D25 −17.7
(c 0.05, MeOH); UV (MeOH) λmax, nm (log ε): 260 (3.59), 302
(4.12); IR (cm−1) νmax: 3320, 2930, 1675, 1638; NMR data, see
Table 2; HRESIMS (m/z): [M + H]+ calcd for C11H13N2O3,
221.0921; found, 221.0923, Δ = 0.90 ppm.
Pseudomobactin B (5): white amorphous solid; [α]D25 −28.8
(c 0.03, MeOH); UV (MeOH) λmax, nm (log ε): 267 (3.19); IR
(cm−1) νmax: 3320, 2930, 1674, 1638, 1205; NMR data, see
Table 2; HRESIMS (m/z): [M + H]+ calcd for C19H21N2O3,
325.1547; found, 325.1550, Δ = 0.92 ppm.
Marfey’s analysis
Samples of compound 2 (150 µg) and 4 (150 µg) were dis-
solved separately in 2 M HCl (100 µL) and heated at 100 °C in
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sealed vials for 16 h. The hydrolysates were concentrated at
40 °C to dryness under a nitrogen stream. The hydrolysates
were treated with 1 M NaHCO3 solution (20 µL) and 1% solu-
tion of ʟ-FDAA (Marfey's reagent, 1-fluoro-2-4-dinitrophenyl-
5-ʟ-alanine amide) in acetone (40 µL). The reaction mixtures
were gently heated at 40 °C for 1 h, after which the solutions
were neutralized by the addition of 1 M HCl (20 µL), diluted
with acetonitrile (100 µL), and filtered through a PTFE mem-
brane filter (0.45 µm). The standard amino acids (ᴅ-Thr, ʟ-Thr,
and ʟ-allo-Thr) were subjected to derivatization with ʟ-FDAA
by using the same method previously described. For the HPLC
analysis, mixtures of the standard amino acid derivatized solu-
tion (5 µL), compound 2 (5 µL) and 4 (5 µL) hydrolysates were
analyzed by injecting into an HPLC Agilent 1260 Infinity
instrument coupled with a Phenomenex C18 analytical column
(5 µm, 4.6 × 150 mm) maintained at 40 °C. The mobile phase
solvents comprised a mixture of A (100% water, 0.1% FA) and
B (100% acetonitrile, 0.1% FA), with a linear gradient elution
mode 10 to 65% CH3CN for 50 min and 65–100% CH3CN over
20 min at a flow rate of 1.0 mL/min and monitored by a diode
array HPLC detector at 340 nm. The HPLC traces were aligned
and visualized using data analysis as shown in Figure S47 (Sup-
porting Information File 1). Retention times (min) for the
derivatized (ʟ-FDAA) threonine standards and for the observed
peaks in the HPLC trace of each ʟ-FDAA-derivatized hydroly-
sis product under the reported conditions were as follows: reten-
tion times of standards: ʟ-Thr: 19.62, ᴅ-Thr: 22.47, ʟ-allo-Thr:
19.83. Retention time (min) for the derivatized (ʟ-FDAA)
threonine presents in 2: ʟ-Thr: 19.63. Retention time (min)
for the derivatized (ʟ-FDAA) threonine presents in 4: ʟ-Thr:
19.64.
Supporting Information
HRESIMS profiles and copies of NMR spectra for
compounds 1–7 in CD3OD including the NMR table of 6
and 7 and copies of UV and IR of compounds 1–5.
Phylogenetic tree showing Pseudomonad sp. DNA
sequence of the bacterial strain UIAU-6B.
Chromatographic profiles of the compounds derivatized
with ʟ-FDAA. Photo of Pseudomonad sp. growing on ISP2
an agar plate. Minimum inhibitory concentration of 1–7 for
vancomycin-sensitive Enterococcus faecium VS144754
and Mycobacterium tuberculosis H37Rv. Experimental
procedure for antimicrobial assays.
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